Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Post-transplant lymphoproliferative disorder (PTLD) is a severe complication of solid organ transplantation, and its manifestation as pleural lymphoma is extremely rare.
This report describes the case of a 34 year old kidney transplant recipient who 2 years post-transplantation presented a sudden onset of massive right-sided pleural effusion, with complete collapse of the ipsilateral lung on thoracic CT scan. Pleural fluid analysis showed an exudative effusion with a lymphocytic predominance, and pleural biopsy confirmed the diagnostic of diffuse large B-cell lymphoma.
The patient was confirmed seronegative for past EBV infection, with absent antibodies to both EBV nuclear antigen (EBNA) and viral capsid antigen (VCA)-IgG. Notably, the EBV viral load in the blood, quantified by polymerase chain reaction (PCR), was also negative at the time of PTLD diagnosis. In contrast, his living-related donor (mother) was seropositive for these markers."
He was maintained on an immunosuppressive regimen of methylprednisolone, tacrolimus, and mycophenolate mofetil (MMF), with no history of rejection or opportunistic infections, and his creatinine and urea levels remained within the normal range.
The therapeutic management consisted of reducing immunosuppressive therapy by switching from tacrolimus to sirolimus, combined with an R-CHOP chemotherapy protocol.
After the third cycle of R-CHOP chemotherapy protocol, the patient developed cardiac decompensation complicated by cardiorespiratory arrest.
The absence of cardiac impairment prior to treatment initiation indicates that the fatal outcome was due to chemotherapy-induced cardiotoxicity, not the PTLD itself.
In conclusion, this case highlights the rarity of PTLD presenting as pleural lymphoma and underscores the critical role of excessive immunosuppression as a risk factor, regardless of its association with EBV. We hope this report will serve clinicians in the future diagnosis and management of this challenging condition.
